ALK
ALK (anaplastic lymphoma kinase) is a member of insulin receptor protein-tyrosine superfamily, functioning in embryonic development and involved in cell survival and cell fate.
Products for ALK
- Cat.No. Product Name Information
-
GC14729
(R)-Crizotinib
PF 2341066
A c-MET and ALK receptor tyrosine kinase inhibitor -
GC13136
(S)-Crizotinib
Potent MTH1 inhibitor
-
GC33319
2-Keto Crizotinib (PF-06260182)
2-Keto Crizotinib (PF-06260182) (PF-06260182) is an active lactam metabolite of crizotinib.
-
GC35280
Alectinib Hydrochloride
Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
-
GC35287
ALK inhibitor 1
ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM).
-
GC17376
ALK inhibitor 2
An inhibitor of TSSK2
-
GC63387
ALK kinase inhibitor-1
ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202.
-
GC73642
ALK-IN-26
ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase.
-
GC73883
ALK-IN-28
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK).
-
GC35289
ALK-IN-5
ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK), with an IC50 of 2.9 nM.
-
GC35290
ALK-IN-6
ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively.
-
GC17283
AP26113
Brigatinib
AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. -
GC14446
ASP3026
ASP 3026;ASP-3026
An ALK inhibitor -
GC14189
AZD-3463
ALK/IGF1R inhibitor
ALK/IGF1R inhibitor -
GC19063
Belizatinib
TSR-011
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. -
GC19508
BLU-782
Activin Receptor-like Kinase 2 Inhibitor 1, ALK2-IN-1, Fidrisertib
BLU-782 is an oral precision therapy specifically designed to selectively target mutant ALK2. -
GC19084
Brigatinib
Brigatinib
A highly potent and selective ALK inhibitor -
GC15145
CEP-28122
anaplastic lymphoma kinase (ALK) inhibitor
-
GC35652
CEP-28122 mesylate salt
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity.
-
GC15273
CEP-37440
FAK/ALK inhibitor,potent and selective
-
GC45789
Ceritinib-d7
LDK 378-d7
An internal standard for the quantification of ceritinib -
GC16025
CH5424802
Alectinib, RO5424802
CH5424802 (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. CH5424802 demonstrates effective central nervous system (CNS) penetration. -
GC12616
Crizotinib hydrochloride
inhibitor of the c-Met kinase and the NPM-ALK
-
GC73579
DDO-2728
DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM.
-
GC14298
DMH-1
BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482
Selective BMP ALK2 receptor -
GC33190
Ensartinib (X-396)
X-396
Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. -
GC32864
Ensartinib hydrochloride (X-396 hydrochloride)
X-396 dihydrochloride
Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. -
GC14476
Entrectinib
NMS-E628, RXDX-101
Orally active inhibitor of ALK kinase -
GC72974
Entrectinib-d8
NMS-E628-d8; RXDX-101-d8
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib. -
GC65380
Envonalkib
Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer.
-
GC36021
F-1
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively.
-
GC73406
Ficonalkib
Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor.
-
GC12273
GSK1838705A
IGF-IR/IR/ALK inhibitor, ATP-competitive
-
GC36222
HG-14-10-04
An ALK inhibitor
-
GC33062
JH-VIII-157-02
JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.
-
GC13902
KRCA 0008
Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor
-
GC14552
LDK378
LDK 378;LDK-378;Ceritinib
LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. -
GC17452
LDK378 dihydrochloride
-
GC50327
LDN 193189 dihydrochloride
DM-3189
Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs -
GC16580
LDN-193189
LDN 193189;LDN193189
ALK inhibitor,potent and selective -
GC17035
LDN-212854
BMP receptor inhibitor,potent and selective
-
GC13225
LDN-214117
potent and selective ALK2 inhibitor
-
GC14931
LDN193189 Hydrochloride
LDN 193189 hydrochloride; LDN-193189 hydrochloride
LDN193189 Hydrochloride is a selective inhibitor of the transcriptionally active morphogenetic protein (BMP) type I receptor, a family of BMP receptors that includes activin receptor-like kinases (ALK1, ALK2, ALK3, and ALK6). LDN193189 Hydrochloride inhibits ALK2 and ALK3 with IC50 values of 5nM and 30nM, respectively. -
GC69422
M4K2234
M4K2234 (compound 26b) is an inhibitor of ALK2. M4K2234 inhibits ALK2 and ALK5 with IC50 values of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for the protein kinases ALK1 and ALK2. M4K2234 can be used in cancer research.
-
GC17582
ML347
LDN193719
BMP receptor inhibitor,potent and selective -
GC65243
MS4077
MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK.
-
GC64966
MS4078
MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK.
-
GC73649
Neladalkib TFA
NVL-655 TFA
Neladalkib TFA is the TFA form of Neladalkib. -
GC14794
PF-06463922
Lorlatinib
PF-06463922 (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor. PF-06463922 has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. PF-06463922 has anticancer activity. -
GC19362
Repotrectinib
TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.
-
GC48070
SB-431542 (hydrate)
Inhibitor of receptors ALK4, ALK5, and ALK7
-
GC14349
SB525334
TGF-β RI Kinase Inhibitor VIII
(TGF-beta1) receptor inhibitor -
GC73129
SIAIS164018 hydrochloride
SIAIS164018 drochloride is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively.
-
GC44903
SMAD3 Inhibitor, SIS3
SMAD3 Inhibitor, SIS3 is a potent and selective inhibitor of Smad3 phosphorylation.
-
GC16694
TAE684 (NVP-TAE684)
TAE 684
A selective ALK inhibitor -
GC50562
TL 13-110
Negative control for TL 13-112
-
GC50563
TL 13-22
Negative control for TL 13-12
-
GC62260
TPX-0131
TPX-0131
TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). TPX-0131 has strong antitumor activities. -
GC62516
UNC5293
UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.
-
GC19140
X-376
X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively.
-
GC62146
XST-14
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.
-
GC64013
ZX-29
ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect.